CPHI North America has reported high attendance on the show flow, as industry investment returns and biologics show significant growth.
This included a 16% increased in buyer attendance, with 4,000 visitors and more than 370 exhibitors making their way to the event.
The organisers have announced that the bioproduction focus of the event will raise to around 50 exhibitors, highlighting the increasing role of North American companies in this field.
Event Manager - Pharma Brand US at Informa Markets, Sarah Griffin, commented: "This year, we have observed and continue to anticipate that supporting the biologics supply chain is crucial to meeting expanding regional needs. This support is a vital aspect of the show, especially as pharmaceutical professionals in North America seek increasingly secure and robust supply chain options within Bioproduction."
Seminars and speeches
More than 80 speakers presented on a wide array of crucial topics in the pharmaceutical sector, including supply chain economics, novel drug manufacturing technologies and industry sustainability initiatives.
BioPlan data released at the event forecasts that bio CDMO growth for small, mid and large companies is expected to return to the normal 10–14% growth rate within the next three to six months.
Looking ahead to 2025, CPHI North America will unveil a much larger dedicated bioproduction area.
This addition comes as a response to several key factors, including capacity constraints at major CMOs, a notable surge in FDA approvals of biologic drugs such as mAbs, advanced therapies and ADCs, as well as a raft of strategic investments by pharmaceutical companies to enhance their bioproduction infrastructure.
